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We report a case of a patient with two B-cell lymphoproliferative disorders: CD5/CD23 B-cell chronic
lymphocytic leukemia and CD5/CD23 mantle cell lymphoma. These disorders were diagnosed simulta-
neously based on flow cytometry, immunohistochemistry, fluorescence in situ hybridization, and polymerase
chain reaction–based molecular studies. The B-cell lymphocytic leukemia clone predominated in the blood
and bone marrow, whereas the mantle cell clone predominated in lymph nodes. Cytometry Part B (Clin.
Cytometry) 51B:41–44, 2003. © 2002 Wiley-Liss, Inc.
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Over recent years, the recognition that lymphoprolif-
erative disorders (LPDs) comprise distinct clinicopatho-
logic entities defined by a combination of morphologic,
immunophenotypic, and genetic features and the avail-
ability of specific therapies for certain of these tumors
make accurate diagnosis imperative. In most cases, de-
tailed immunophenotypic analysis of the leukemia/lym-
phoma cells contributes to a specific classification. In fact,
the pattern of reactivity for CD20, CD23, CD79b, FMC7,
surface immunoglobulins (Igs), and adhesion molecules
proved to be of great help in distinguish between small
lymphocytic lymphoma/chronic lymphocytic leukemia
(CLL) and mantle cell lymphoma (MCL) (1–5). Moreover,
techniques based on polymerase chain reaction (PCR) and
fluorescence in situ hybridization (FISH) to detect specific
molecular and chromosomal abnormalities (6,7) and the
use of antibodies against novel fusion proteins (8,9)
greatly improved the ability to detect specific genetic
abnormalities. For instance, the chromosomal transloca-
tion (11;14)(q13;q32) that fuses the IGH and CCND1
genes and leads to cyclin D1 overexpression has been
identified as the genetic hallmark of MCL (10). Although
an equivalent genetic marker has not been found for
B-CLL, numerical or structural chromosomal abnormalities
are detected by conventional cytogenetics or FISH analysis
in 50% of B-CLL cases, the most common changes being
the trisomy 12 and the structural abnormalities of 13q,
11q, 6q, 14q, and 17p (11,12). Karyotypic analysis and
FISH- and PCR-based molecular studies may be helpful in
clarifying the diagnosis especially when the B-cell LPD is
difficult to classify based on clinical, morphologic, and
phenotypic grounds such as in establishing the differential
diagnosis between an MCL and a morphologically atypical
B-CLL (13–15) and in identifying B-CLL forms with specific
chromosomal abnormalities with prognostic significance
(11,16)
We report a case of a patient in whom a CD5/CD23
B-CLL and CD5/CD23 MCL were diagnosed simulta-
neously based on flow cytometry and FISH- and PCR-based
molecular studies. Aside from the rarity of a true CD5/
CD23 B-CLL, to the best of our knowledge, this is the
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first report documenting the simultaneous diagnosis of a
B-CLL and an MCL.
CASE REPORT
An 86-year-old man was evaluated at the Hematology
Department of the Hospital Geral de Santo Anto´nio (Porto,
Portugal) for persistent, absolute lymphocytosis and ad-
renomegalies. White blood cell count was 16.4 109/liter
(neutrophils, 22%; lymphocytes, 74%), hemoglobin was
9.1 g/dl, and platelet count was 201  109/liter. The
physical examination revealed multiple cervical, axillary,
and inguinal adrenomegalies and hepatomegaly.
The peripheral blood (PB) smear showed a marked
predominance of small lymphocytes with clumped chro-
matin and scarce cytoplasm and a small population
(15%) of large lymphoid cells with less condensed chro-
matin, frequently with a visible nucleoli and a more abun-
dant, sometimes basophilic, cytoplasm. Gumprecht’s
shadows also were present. Flow cytometry–based immu-
nophenotyping of PB lymphocytes revealed two popula-
tions of phenotypically abnormal B cells (Fig. 1A). The
first one, comprising 90% of B cells, consisted of CD19,
CD22low, CD23high, CD25low, FMC7, CD5, CD10,
CD11a, CD11c, CD20, CD38, CD79b, CD103, and
surface and cytoplasmic Ig. The second population, com-
prising only 10% of B cells, consisted of CD19, CD20high,
CD22high, CD25low, CD38low, CD79b, FMC7, CD5,
CD10, CD11a, CD11c, CD23, CD103, and surface
Ighigh (IgM, ). A few (1%) residual polyclonal B cells
were also present. FISH analysis showed the (11;14) trans-
location in only 9% of PB lymphocytes (Fig. 2A) and the
13q14.3 deletion in another 21% (Fig. 2B); trisomy 12 and
the (14;18) translocation were not detected (data not
shown).
On bone marrow smears, lymphocytes comprised 60%
of the total cells counted, and immunophenotyping stud-
ies revealed that most (59%) were B cells consisting of
CD19/CD5/CD23/surface Ig (73%) and CD19/
CD5/CD23/ chains (27%), mature B lymphocytes,
and a few residual CD19/CD20/CD38high/CD10/sur-
face Ig B-cell precursors (1%). The bone marrow tre-
phine biopsy showed a mixed nodular and interstitial
infiltration pattern consisting mainly of CD20/CD5/
CD23 small lymphocytes.
Flow cytometry of lymph node (LN) lymphocytes
showed that most (90%) had a CD5/CD23/ immuno-
phenotype, whereas CD5/CD23high/Ig B cells com-
prised only 10% of LN lymphocytes (Fig. 1B). FISH analysis
showed the t(11;14)(q13;q32) in 94% of LN cells (Fig. 2C).
The LN histology was consistent with MCL, and immuno-
histochemical studies confirmed that most B-lymphoma
cells expressed CD20 and CD5 and were negative for
CD23; a few CD23 B lymphocytes also were observed.
PCR-based IgH rearrangement molecular studies con-
firmed that the B-cell clone found in the LN was different
from the one that predominated in blood (Fig. 3).
DISCUSSION
An increasing number of cases of biclonal B-cell LPD
have been reported in the past few years, likely a conse-
quence of a more accurate laboratorian approach to diag-
nosis (17–20); in most of these cases, two different cell
populations were detected by flow cytometry, and, unless
they express different Ig light chains, additional studies
are usually necessary to distinguish a true biclonal disease
from phenotypic heterogeneity due to intraclonal diver-
sity. Only a few cases in which two distinct B-cell popu-
FIG. 1. Dot plots showing the main immunophenotyping characteristics of peripheral blood (A) and lymph node (B) B cells. CD19/CD5 B
lymphocytes are represented as blue dots and CD19/CD5 B lymphocytes are represented as red dots. Gray dots represent CD19 white blood cells.
Flow cytometric studies were performed by using a method of staining and washing lyses (FACS lysing solution, Becton Dickinson, San Jose, CA) and
four-color staining that combined allophycocyanin-conjugated anti-CD19 and phycoerythrin–cyanine 5 conjugated anti-CD5 with a large panel of other
phycoerythrin and fluorescein isothiocyanate conjugated monoclonal antibodies directed against other markers combined as follows: FMC7/CD23,
CD20/CD22, CD10/CD38, CD103/CD25, CD21/CD79b, CD11a/HLA-DR, / chains. Other specific combinations were used whenever necessary to
better discriminate the B-cell populations. Data acquisition was carried out in a FACScalibur flow cytometer equipped with a 488-nm argon laser and
a 635-nm red-diode laser (Becton Dickinson). For data analysis, Paint-a-Gate PRO software (Becton Dickinson) was used. FSC, forward scatter; SSC, side
scatter.
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lations have been identified fulfill the criteria for diagnosis
of two different entities (21).
The rare biclonal B-cell LPD described here requires
further discussion concerning two points: the criteria for
diagnosis of a CD5 B-CLL and its association with a CD5
MCL.
Although expression of the CD5 antigen by neoplastic
cells is considered an important criterion for diagnosis of
B-CLL, published series have frequently included a num-
ber of “CD5 B-CLL” cases. A careful review of cases that
had been classified as “CD5 B-CLL” showed that most
had other unusual immunophenotypic features, including
bright-surface Ig expression, bright CD20 expression, and
absence of CD23 expression, and displayed an adhesion
molecule profile resembling Non Hodgkin Lymphoma
(NHL), suggesting that the majority of them represented
NHL in the leukemic phase rather than CD5 B-CLL
(22,23). Nonetheless, it is usually accepted that CD5
B-CLL, although rare, does exist. We are convinced that
the present case is one of the very rare cases of CD5
B-CLL because it met all the immunophenotypic criteria
for the diagnosis of B-CLL except the expression of CD5
and the arbor 13q14.3 deletion, a structural abnormality
commonly observed in B-CLL; moreover, the lymphocyte
morphology was that usually observed in typical CD5
B-CLL and the possibility of a CD10 follicular cell lym-
phoma was ruled out by immunophenotypic and FISH
studies.
Concerning the characterization of the CD5 B-cell
population that accounted for only a minority of PB lym-
phocytes and predominated in LN, its characteristic
CD5, CD23, FMC7, CD20high, CD22high, surface
Ighigh immunophenotype strongly pointed to the diagno-
sis of an MCL and made improbable the diagnosis of a
B-CLL, a CD5 B-cell LPD that typically displays a CD23,
FMC7, CD20/low, CD22/low, and surface Ig/low
FIG. 2. Fluorescence in situ hybridization (FISH) images showing the
t(11;14) translocation (A) and the 3q14.3 deletion (B) that were found in
9% and 24% of blood cells, respectively. C shows the t(11;14) translo-
cation in most (94%) lymph node cells. The t(11;14) translocation is
detected by the presence of a yellow FISH spot in the cells at the left
parts of A and C, in addition to the normal red and green FISH spots
observed in other cells from the same sample (right parts of A and C). The
3q14.3 deletion is demonstrated by the presence of one red FISH spot
in the cell at the left part of B, in opposition to the two normal red FISH
spots in other cells from the same sample (right part of B). Fluorescence
hybridization studies were performed with the following DNA probes:
IGH-specific BAC (covering the JH and first constant regions) and
CCND1-specific probes to detect the IGH-CCND1 fusion gene associated
with the t(11;14)(11q13;14q32) translocation (LSI IGH/CCND1); a
D13S319 locus-specific probe to detect del(13q14.3) structural abnor-
malities (LSI D13S319).
FIG. 3. Molecular identification of immunoglobulin H rearrangement
clonality in samples of peripheral blood (lane 3) and lymph node (lane 4).
Lanes 1 and 2 show molecular weight markers (500-bp ladder in lane 1
and 100-bp ladder in lane 2). The lymph node was found to harbor a
B-cell clone with a molecular weight different from that predominating in
the peripheral blood. Molecular studies were performed with the B-
Lymphoma Molecular Diagnostic Kit from MD-Master Diagnostica
(Granada, Spain) as recommended by the manufacturer. Peripheral
blood DNA was extracted by using a semi-automated procedure with the
Nuclisens Extractor (Organon Technika Corporation, Durham, North
Carolina); lymph node DNA was extracted with the Extracell Kit (Ampli-
medica spa-Bioline, Torino, Italy).
43B-CLL AND MCL
phenotype (4,24–26). FISH studies confirmed our suspi-
cion by revealing the presence of the typical chromo-
somal abnormality t(11;14)(q13;q32).
To the best of our knowledge, this is the first case in
which a rare form of 13q14.3/CD5 B-CLL was associ-
ated with a typical t(11;14)(q13;q32)/CD5 MCL, with
each LPD predominating in different compartments
(blood/bone marrow and lymph nodes).
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